Search

Displaying results 3531 - 3540 of 4284 in total
  1. Drug

    OC-1012

    go.drugbank.com/drugs/DB05834
    Experimental

    OC-1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of mucositis, a serious side effect of chemotherapy and head and neck radiation therapy.

  2. Drug

    Caramiphen

    go.drugbank.com/drugs/DB11504
    ExperimentalVet approved

    Additionally, it is used, in combination with [phenylpropanolamine], as a cough suppressant and nasal decongestant for the symptomatic treatment of seasonal respiratory conditions.

  3. Drug

    2,4-Dinitrophenol

    go.drugbank.com/drugs/DB04528
    Experimental

    It is also used as a metabolic stimulant. (Stedman, 26th ed)

  4. Drug

    Citraconic acid

    go.drugbank.com/drugs/DB04734
    Experimental

    Citraconic acid is one of the isomeric dicarboxylic acids produced by the distillation of citric acid, or as metabolites by microorganisms, cis-CH3-C(CO2H)=CHCO2H; the trans-isomer is mesaconic acid.

  5. Drug

    3-Allylfentanyl

    go.drugbank.com/drugs/DB09169
    ExperimentalIllicit

    Fentanyl and its analogs have killed thousands of people around the world as drugs of abuse.

  6. Drug

    Zilebesiran

    go.drugbank.com/drugs/DB18929
    Investigational

    Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care

  7. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  8. Drug

    Afelimomab

    go.drugbank.com/drugs/DB04956
    Experimental

    Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.

  9. Drug

    PM02734

    go.drugbank.com/drugs/DB05158
    Investigational

    PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.

  10. Drug

    PF-06291874

    go.drugbank.com/drugs/DB15065
    Investigational

    PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes